Nanoparticle compositions containing sugar functionalized nucleic acid carriers
Inventors
Talukder, Poulami • CHAHAL, Jasdave
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Nanoparticle compositions for delivery of nucleic acids to subjects including carriers comprising sugar functionalized nucleic acid carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the delivery molecules are described. Methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects are provided.
Core Innovation
The disclosure relates to a nucleic acid carrier comprising a structure of formula Ia, formula Ib, formula Ie, and formula If. In the carrier, A is an amine linker, B is a hydrophobic unit, n values range from 0 to 20, and Y is a sugar moiety.
The disclosure further describes sugar-functionalized nucleic acid carriers and multiple sugar-/deoxy-sugar-modified amphiphilic dendron carriers, including deoxy sugar moiety Z. The carrier concept is described using PE-G2-alkyne-BocAmine dendron scaffolds, azide-bearing sugars, and introduction of a hydrophobic unit via fatty acid functional reagent or ricinoleic-NHS to create amphiphilic dendron carriers.
Nanoparticle compositions include the nucleic acid carrier and an agent enclosed therein, where the enclosed agent is a nucleic acid, including polynucleotide, oligonucleotide, DNA, cDNA, RNA, repRNA, siRNA, miRNA, sgRNA, and mRNA. The disclosure additionally describes using the nanoparticle composition for treating a disease or condition by administering a therapeutically effective amount to a subject in need thereof.
Claims Coverage
The independent claims identified are a nucleic acid carrier claim, a nanoparticle composition claim, and a method-of-treatment claim. Across these independent claims, three main inventive elements are the defined nucleic acid carrier structure, the nanoparticle enclosure of an agent within that carrier, and administration of a therapeutically effective amount of the nanoparticle composition for treatment.
Nucleic acid carrier defined by formula Ia, Ib, Ie, and If
A nucleic acid carrier comprising a structure of formula Ia, formula Ib, formula Ie, and formula If, wherein A is an amine linker, B is a hydrophobic unit, n values from 0 to 20, and Y is a sugar moiety.
Nanoparticle composition with carrier and enclosed agent
A nanoparticle composition comprising a nucleic acid carrier and an agent enclosed therein, the nucleic acid carrier comprising a structure of formula Ia, formula Ib, formula Ie, and formula If, wherein A is an amine linker, B is a hydrophobic unit, n values from 0 to 20, and Y is a sugar moiety.
Method of treating a disease or condition using therapeutically effective nanoparticle administration
A method for treating a disease or condition in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a nanoparticle composition, the nanoparticle composition comprising a nucleic acid carrier and an agent enclosed therein, and the nucleic acid carrier comprising a structure of formula Ia, formula Ib, formula Ie, and formula If, wherein A is an amine linker, B is a hydrophobic unit, n values from 0 to 20, and Y is a sugar moiety.
Overall, the claim coverage centers on a nucleic acid carrier defined by formulas Ia, Ib, Ie, and If with A as an amine linker, B as a hydrophobic unit with n from 0 to 20, and Y as a sugar moiety; this carrier is then used in a nanoparticle composition that encloses an agent or in a method of treating a disease or condition by administering a therapeutically effective amount of that nanoparticle composition.
Stated Advantages
Improved gene delivery attributed to carbohydrate biocompatibility/targeting.
Tracking via isotopically labeled fatty acids.
Hydrophobic units enable self-assembly.
Sugar moieties improve biocompatibility/loading.
Documented Applications
Treatment of a disease or condition in a subject by administering a therapeutically effective amount of a nanoparticle composition.
Therapeutic/immunogenic nucleic-acid delivery using nanoparticle compositions, including nucleic acids selected from repRNA, siRNA, miRNA, sgRNA, and mRNA, including antigen-encoding.
In vivo SEAP mRNA expression comparisons dependent on PEG-lipid type are described.
Interested in licensing this patent?